New peer-reviewed data from the Phase III PEARL study (GEICAM/2013-02) published in the European Journal of Cancer confirms that DiviTum TKa can detect treatment-specific biological responses early in HR+/HER2- metastatic breast cancer. While largely confirmatory, the treatment-dependent dynamics add meaningful differentiation versus standard biomarkers.
LÄS MER
